50 results about "Solid oral dosage form" patented technology

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

Disclosed herein are pharmaceutical oral solid dosage forms comprising a salt of liothyronin and a salt of levothyroxine, and methods of making and using the pharmaceutical oral solid dosage forms.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

This invention provides methods, systems and devices for personal, secure authenticated provision of oral solid dosage forms, administered as a dosage regimen which may be altered over time. The methods and systems rely on providing a device for personal secure administration of oral solid dosage forms to a subject, where the device comprises a plurality of individually addressable oral dosage forms contained therein, wherein a first oral dosage form of the plurality contained therein differs from that of at least a second oral dosage form of the plurality, in terms of an active ingredient type, an active ingredient dosage, or a composition component of said solid oral dosage form, or any combination thereof and wherein the device provides for dispensing at least one individually addressable oral dosage form contained therein following a personal authentication protocol and wherein the device is subject to programming, which programming controls distribution of said oral dosage forms contained therein according to a first secure distribution program and wherein the device comprises a user interface and optionally at least one sensor and wherein subject response data, sensor collected data, or testing result data or any combination thereof is collected and incorporated in the programming; and_whereby the programming controls adjusting, altering or overwriting the first distribution program via a secure protocol to a second distribution program, as a function of the collected subject response data, sensor collected data, or testing result data or any combination thereof and completing an authentication protocol for dispensing the oral dosage form to the subject and dispensing the first oral dosage form within an oral cavity of the subject and following secure communication with an authorized provider,enabling adjustment, alteration or overwriting of the programming to activate the second oral dosage form distribution program in the device; and_dispensing the oral dosage forms of the second oral dosage form distribution program to the subject, whereby an oral dosage form regimen is adjusted, altered or overwritten in the device resulting in altering dispensing of the oral dosage form, by means of a secure authenticated protocol.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to the pharmaceutical compositions comprising nor-UDCA or pharmaceutically acceptable salt or ester thereof and the process for preparation. The present invention most preferably discloses the solid oral dosage form of nor-UDCA preferably in the form of tablets, capsules, disintegrating tablets and effervescent tablets.

Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt % to about 70 wt %, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant are disclosed, as are uses thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present disclosure provides a solid oral dosage form comprising bicotegravir, or a pharmaceutically acceptable salt thereof, and lenacavir, or a pharmaceutically acceptable salt thereof.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present invention relates to an oral solid dosage form comprising ticagrelor as pharmaceutically active ingredient and at least one excipient. In particular, the present invention relates to a process for producing an immediate release ticagrelor tablet composition which is wet granulated with croscarmellose sodium or sodium starch glycolate as a disintegrant in order to produce stable in vitro dissolution profile throughout the shelf-life.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

This invention relates to novel pharmaceutical formulations, including solid oral dosage forms containing the non-psychoactive cannabidiol (CBD). The invention also relates to methods for preparing the pharmaceutical formulation and its application in treating diseases and conditions.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

A semi-solid oral dosage form that includes one or more excipients, an active ingredient, and a polymer. The polymer encapsulates at least a portion of the active ingredient, and the portion of the active ingredient that is encapsulated does not come in direct contact with the one or more excipients present in the semi-solid oral dosage form. The semi-solid oral dosage form can be, e.g., an oral thin film (OTF) or gummy. Also provided is a method of orally administering the semi-solid oral dosage form, as well as methods of manufacturing the semi-solid oral dosage form.

A dissolvable solid oral dosage form is disclosed, the dosage form comprising a first nicotine form and a second nicotine form, the dosage form having a disintegration time of no more than 10 minutes, wherein the first nicotine form and the second nicotine form are different, wherein the second nicotine form is a delayed nicotine form.

Oral solid dosage forms including porcine thyroid powder and methods of making and using the oral solid dosage forms are disclosed.

The present disclosure relates to pharmaceutical compositions comprising vamorolone, wherein the pharmaceutical composition is a solid oral dosage form. The present disclosure also relates to processes for preparing the pharmaceutical compositions disclosed herein and methods of treating muscular dystrophy comprising administering the pharmaceutical compositions disclosed herein to a subject.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt theroof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Disclosed herein are solid oral dosage forms comprising Compound A:, or a pharmaceutically acceptable salt thereof.

The present invention relates to a solid oral dosage form for sustained release in the lower gastrointestinal tract comprising an antibody or a functional fragment thereof in a depot layer (2) covering an inert core unit (1), a sustained release layer (3) covering the depot layer and a delayed release layer (4) covering the sustained release layer, preferably prepared by pharmaceutical stratification; an oral multiparticulate drug delivery system comprising a plurality of such solid oral dosage forms; and the use of the solid oral dosage form in targeted topical treatment in the lower gastrointestinal tract of a patient.

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

The present disclosure relates to a pharmaceutical composition comprising dapagliflozin and sitagliptin, and method of preparation thereof. More particularly, dapagliflozin is present as dapagliflozin propanediol monohydrate, and sitagliptin is present as sitagliptin phosphate monohydrate. Furthermore, the present disclosure provides methods including wet granulation, dry granulation and direct compression for preparing fixed dose composition(s). The fixed dose composition is available in solid oral dosage forms, such as a tablet, capsule or sachet, wherein the tablet can be monolayer or bilayer tablet. The said composition is uniform, effective, stable to simplify management regimens, enhance subject adherence, and provide sustained glycaemic control in management of Type 2 Diabetes Mellitus.

The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.

A pharmaceutical formulation, particularly a solid oral dosage form (e.g., tablet), is disclosed, and its use is also disclosed, which includes (i) a compound of Formula I in an amount of about 40 wt% to about 70 wt%, (ii) a filler, (iii) a disintegrant, (iv) and a lubricant. Pharmaceutical formulations suitable for treating viral infections, such as coronavirus infections, pneumoviridae virus infections, picornaviridae virus infections, flaviviridae virus infections, orthomyxovirus infections, and paramyxoviridae virus infections, are provided.

The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

The present invention discloses high-purity oral solid dosage forms comprising sacubitril, valsartan, its complex or pharmaceutically acceptable salts thereof, and an SGLT-2 inhibitor or pharmaceutically acceptable salts thereof, together with one or more pharmaceutically acceptable excipients, wherein the active ingredients are in a single-compartment form, without physical separation between them, distributed uniformly and homogeneously.